eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Companyâ€™s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Real-time BOERSE MUENCHEN Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-

10/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
07/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI

Market Cap	940 816.95 762.72 700.19 1.32K 89.6K 1.34K 8.99K 3.52K 44.68K 3.53K 3.45K 147K	P/E 2022	-0.78x	P/E 2023	-0.71x
Enterprise Value	2.18M 1.89M 1.77M 1.62M 3.06M 207M 3.11M 20.82M 8.15M 103M 8.17M 7.99M 341M	EV / Sales 2022	3,344,920x	EV / Sales 2023	-
Free-Float	99.75%	Yield 2022 *	-	Yield 2023	-

10/09/24	Tyra Biosciences Names Doug Warner Chief Medical Officer	MT
07/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from S&P TMI Index	CI
01/07/24	EFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index	CI
24/06/24	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
24/06/24	Top Midday Decliners	MT
24/06/24	EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	MT
24/06/24	EFFECTOR Therapeutics, Inc. Announces Cessation of Michael Byrnes, Chief Financial Officer	CI
24/06/24	Effector Therapeutics, Inc. Terminates Its Employees in Connection with the Planned Wind Down of the Company?s Operations	CI
24/06/24	Effector Therapeutics, Inc. Announces Director Resignations	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
24/06/24	EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	CI
20/05/24	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
09/05/24	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

24/08/23	HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	MT
26/05/23	Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	MT
10/05/23	Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	MT
09/03/23	Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	MT
09/01/23	JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	MT

eFFECTOR Therapeutics, Inc. Share Price BOERSE MUENCHEN

Stocks

LWK

US28202V2079

Biotechnology & Medical Research

Valuation: eFFECTOR Therapeutics, Inc.

Latest news : eFFECTOR Therapeutics, Inc.

Analysts' recommendations: eFFECTOR Therapeutics, Inc.

Press Releases: eFFECTOR Therapeutics, Inc.

Managers and Directors: eFFECTOR Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/08/24	FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer	AQ
26/06/24	EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	PU
24/06/24	EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	AQ
04/04/24	EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	AQ
05/02/24	EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EFFECTOR THERAPEUTICS, INC.	-.--%	-.--%	-	-	940
WUXI APPTEC CO., LTD.	+0.05%	+2.80%	+38.17%	+74.12%	56.54B
ARGENX SE	-3.06%	-10.22%	+23.62%	+58.59%	53.6B
BIONTECH SE	+1.84%	+3.27%	-14.06%	-12.13%	22.91B
INSMED INCORPORATED	-0.15%	-7.92%	-9.42%	+352.23%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+0.15%	-0.77%	+23.76%	-11.52%	20.27B
GENMAB A/S	-0.67%	-1.73%	+33.09%	-31.09%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.45%	-7.24%	+17.67%	+563.14%	14.75B
PHARMAESSENTIA CORPORATION	+9.91%	+2.64%	+188.84%	+326.19%	13.53B
EXELIXIS, INC.	+3.83%	-0.56%	+47.77%	+170.70%	13.33B
Average	+1.16%	-1.88%	+38.83%	+165.58%	25.98B
Weighted average by Cap.	+0.14%	-1.70%	+31.71%	+123.13%

	2022	2023
Net sales	3.55 3.09 2.88 2.65 4.99 338.66 5.08 33.99 13.31 168.88 13.35 13.05 557.04	-
Net income	-22.66M -19.7M -18.39M -16.88M -31.83M -2.16B -32.39M -217M -84.93M -1.08B -85.13M -83.25M -3.55B	-35.81M -31.12M -29.06M -26.67M -50.3M -3.41B -51.17M -343M -134M -1.7B -135M -132M -5.61B
Net Debt	-6.03M -5.24M -4.89M -4.49M -8.47M -575M -8.62M -57.68M -22.59M -287M -22.65M -22.14M -945M	2.18M 1.89M 1.76M 1.62M 3.05M 207M 3.11M 20.81M 8.15M 103M 8.17M 7.99M 341M